|
|
Volumn 32, Issue 3, 2014, Pages 229-238
|
|
Nature biotechnology's academic spinouts of 2013
a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
APOLIPOPROTEIN B;
CELL ADHESION MOLECULE;
COMPLEMENTARY DNA;
COP9 SIGNALOSOME;
FIBRINOGEN;
HALORHODOPSIN;
HYPOXIA INDUCIBLE FACTOR;
IMMUNOGLOBULIN A ANTIBODY;
IMMUNOGLOBULIN G4;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
PROTEIN;
PROTEINASE ACTIVATED RECEPTOR 1;
RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR;
REGULATOR PROTEIN;
RNA 16S;
RNA INDUCED SILENCING COMPLEX;
SMALL INTERFERING RNA;
THROMBIN;
UNCLASSIFIED DRUG;
VISUAL PIGMENT;
VON HIPPEL LINDAU PROTEIN;
WARFARIN;
XO1 PROTEIN;
ACUTE CORONARY SYNDROME;
ACUTE GRANULOCYTIC LEUKEMIA;
ADENO ASSOCIATED VIRUS;
AGGRESOME;
AGRONOMIC TRAIT;
ANTICOAGULATION;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARABIDOPSIS THALIANA;
ARTICLE;
AUTOPHAGOSOME;
AUTOPHAGY;
B LYMPHOCYTE;
BEETLE;
BINDING SITE;
BIOINFORMATICS;
BIOTECHNOLOGY;
BLEEDING;
BLOOD CLOTTING;
BRAIN HEMORRHAGE;
CANCER IMMUNOTHERAPY;
CELL CYCLE REGULATION;
CELL FATE;
CELL MEMBRANE;
CELL SURFACE;
CELL SURVIVAL;
CELL THERAPY;
CHROMATIN IMMUNOPRECIPITATION;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL (TOPIC);
CROSS REACTION;
CRYSTAL STRUCTURE;
DAMPING OFF DISEASE;
DEEP VEIN THROMBOSIS;
DEVELOPMENTAL STAGE;
DISEASE RESISTANCE;
DNA SEQUENCE;
DRUG APPROVAL;
DRUG DEVELOPMENT;
DRUG INTERACTION;
EFFECTOR CELL;
ENDOPLASMIC RETICULUM;
ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION;
ENHANCER REGION;
EYE DISEASE;
FINANCIAL MANAGEMENT;
FOLLICULAR LYMPHOMA;
GENE CONSTRUCT;
GENE CONTROL;
GENE MUTATION;
GENE SILENCING;
GENE THERAPY;
GENETIC CODE;
GENETIC DISORDER;
GLOBAL CLIMATE;
GOOD MANUFACTURING PRACTICE;
GREENHOUSE;
HARVEST;
HEAD INJURY;
HEART ATRIUM FIBRILLATION;
HEMATOLOGIC MALIGNANCY;
HEMOPHILIA;
HEMOPHILIA B;
HIGH THROUGHPUT SEQUENCING;
HODGKIN DISEASE;
HUMAN;
IMMUNE RESPONSE;
IN VITRO STUDY;
INSULIN DEPENDENT DIABETES MELLITUS;
LEBER CONGENITAL AMAUROSIS;
LEBER HEREDITARY OPTIC NEUROPATHY;
LEPIDOPTERA;
LIVER CELL;
LUNG EMBOLISM;
LYMPHATIC LEUKEMIA;
LYSOSOME;
MAIZE;
MANTLE CELL LYMPHOMA;
MICROBIOME;
MITOCHONDRION;
MULTIPLE MYELOMA;
MYELOMA;
NATRONOMONAS PHARAONIS;
NATURAL SCIENCE;
NEMATODE;
NEUROBLASTOMA;
NONHUMAN;
NUCLEOTIDE SEQUENCE;
ONCOGENE MYC;
OOMYCETES;
OPEN READING FRAME;
OPTOGENETICS;
PATENT;
PEST CONTROL;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PHENOTYPE;
PHOTORECEPTOR CELL;
PHOTOSENSITIVITY;
PLANT;
PRIORITY JOURNAL;
PROGNOSIS;
PROGRESSION FREE SURVIVAL;
PROTEIN DEGRADATION;
PROTEIN HOMEOSTASIS;
PROTEIN PROCESSING;
PROTEIN TARGETING;
REMISSION;
RETINITIS PIGMENTOSA;
RHIZOCTONIA;
RHIZOSPHERE;
RNA INTERFERENCE;
RNA TRANSLATION;
ROOT ROT;
SEROTYPE;
SINGLE NUCLEOTIDE POLYMORPHISM;
SOYBEAN;
SYSTEMIC LUPUS ERYTHEMATOSUS;
T LYMPHOCYTE;
TARGET CELL;
THROMBOEMBOLISM;
TRANSGENIC CROP;
TUMOR GROWTH;
UBIQUITINATION;
UNITED STATES;
VENOUS THROMBOEMBOLISM;
VIRUS INFECTION;
VISION;
VISUAL IMPAIRMENT;
ADOPTIVE TRANSFER;
ECONOMICS;
MICROFLORA;
ORGANIZATION AND MANAGEMENT;
PROCEDURES;
TRANSGENIC PLANT;
TRENDS;
ADOPTIVE TRANSFER;
BIOTECHNOLOGY;
GENETIC THERAPY;
HUMANS;
MICROBIOTA;
PLANTS, GENETICALLY MODIFIED;
PROTEINS;
RNA INTERFERENCE;
|
|
EID: 84898655351
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.2846 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|